VEGF-A, sVEGFR-1, and sVEGFR-2 in BCR-ABL negative myeloproliferative neoplasms

Vainchenker, 2011, New mutations and pathogenesis of myeloproliferative neoplasms, Blood, 118, 1723, 10.1182/blood-2011-02-292102 Ribatti, 2005, The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review, Br J Haematol, 128, 303, 10.1111/j.1365-2141.2004.05291.x Yang, 2012, The role of vascular endothelial growth factor in ossification, IJOS, 4, 64, 10.1038/ijos.2012.33 Brockington, 2004, Vascular endothelial growth factor and the nervous system, Neuropathol Appl Neurobiol, 30, 427, 10.1111/j.1365-2990.2004.00600.x Wang, 2004, Targeting autocrine and paracrine VEGF receptor pathway inhibits human lymphoma xenografts in vivo, Blood, 104, 2893, 10.1182/blood-2004-01-0226 Thielemann, 2010, Assessment of sVEGFR-1 concentration in patients with breast cancer, Współcz Onkol, 14, 189 Dai, 2007, VEGF: an essential mediator of both angiogenesis and endochondral ossification, J Dent Res, 86, 937, 10.1177/154405910708601006 Wierzbowska, 2003, Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia, Eur Cytokine Netw, 14, 149 Sallinen, 2014, Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer, BMC Cancer, 14, 696, 10.1186/1471-2407-14-696 Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, 114, 937, 10.1182/blood-2009-03-209262 Bremnes, 2006, Angiogenesis In non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood, Lung Cancer, 51, 143, 10.1016/j.lungcan.2005.09.005 Lesslie, 2006, Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases, Br J Cancer, 94, 1710, 10.1038/sj.bjc.6603143 Kraft, 1999, Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease, Cancer, 85, 178, 10.1002/(SICI)1097-0142(19990101)85:1<178::AID-CNCR25>3.0.CO;2-7 Wąsik-Szczepanek, 2008, Vascular endothelial growth factor (VEGF) and its role in B-cell chronic lymphocytic leukemia, Acta Haematol Pol, 39, 197 Aguayo, 2002, Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes, Cancer, 95, 1923, 10.1002/cncr.10900 Verstovsek, 2002, Clinical relevance of vascular endothelial growth factors 1 and 2 in acute myeloid leukemia and myelodysplastic syndrome, Br J Haematol, 118, 151, 10.1046/j.1365-2141.2002.03551.x Bellamy, 2001, Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes, Blood, 97, 1427, 10.1182/blood.V97.5.1427 Medinger, 2009, Angiogenesis and vascular endothelial growth factor -/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status, Br J Haematol, 146, 150, 10.1111/j.1365-2141.2009.07726.x Gianelli, 2007, VEGF expression correlates with microvessel density in Philadelphia chromosome-negative chronic myeloproliferative disorders, Am J Clin Pathol, 128, 966, 10.1309/FP0N3LC8MBJUFFA6 Medinger, 2010, Clinical trials with anti-angiogenic agents in hematological malignancies, J Angiogenes Res, 2, 10, 10.1186/2040-2384-2-10 Krasowska-Kwiecień, 2009, Angiogenesis in different clinical phases of chronic myeloid leukemia, Przegl Lek, 66, 471 Musolino, 2002, Soluble angiogenic factor: implications for chronic myeloproliferative disorders, Am J Hematol, 69, 159, 10.1002/ajh.10020 Maktouf, 2011, Evaluation of serum VEGF levels in untreated erythrocytosis patients, Pathol Biol (Paris), 59, 240, 10.1016/j.patbio.2010.02.005 Alonci, 2008, Evaluation of circulating endothelial cells, VEGF and VEGFR2 serum levels in patients with chronic myeloproliferative diseases, Hematol Oncol, 26, 235, 10.1002/hon.865 Panteli, 2007, Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases, Hematology, 12, 481, 10.1080/10245330701554664 Aref, 2005, Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient outcome, Hematology, 10, 131, 10.1080/10245330500065797 Möhle, 1997, Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets, Proc Natl Acad Sci U S A, 94, 663, 10.1073/pnas.94.2.663 Misso, 2007, Evaluation of vascular endothelial growth factor, fibroblast growth factor and thrombopoietin serum levels in myeloproliferative diseases, Congr Eur Hematol Assoc Hu, 2004, Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes, Cancer, 100, 1884, 10.1002/cncr.20187 Ratajczak, 1998, Role of vascular endothelial growth factor (VEGF) and placenta-derived growth factor (PlGF) in regulating human haemopoietic cell growth, Br J Haematol, 103, 969, 10.1046/j.1365-2141.1998.01076.x Treliński, 2010, Circulating endothelial cells in essential thrombocythemia and polycythemia vera: correlation with JAK2-V617F mutational status, angiogenic factors and coagulation activation markers, Int J Hematol, 91, 792, 10.1007/s12185-010-0596-7 Wu, 2010, A systems biology perspective on sVEGFR1: its biological function, pathogenic role and therapeutic use, J Cell Mol Med, 14, 528 Boiocchi, 2011, Increased expression of vascular endothelial growth factor receptor 1 correlates with VEGF and microvessel density in Philadelphia chromosome-negative myeloproliferative neoplasms, J Clin Pathol, 64, 226, 10.1136/jcp.2010.083386